Evaluation of the in vitro activity of voriconazole as predictive of in vivo outcome in a murine aspergillus fumigatus infection model

Valentina Salas, F. Javier Pastor, Enrique Calvo, Deanna A. Sutton, Annette W. Fothergill, Josep Guarro

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We have evaluated the in vitro activity of voriconazole against 61 strains of Aspergillus fumigatus by using broth microdilution, disk diffusion, and minimal fungicidal concentration procedures. We observed an excellent correlation between the results obtained with the three methods. Five percent of the strains showed MICs greater than or equal to the epidemiological cutoff value (ECV; 1 μg/ml). To assess whether MICs were predictive of in vivo outcome, we tested the efficacy of voriconazole at 25 mg/kg of body weight daily in an immunosuppressed murine model of disseminated infection using 10 strains representing various patterns of susceptibility to the drug as determined by the in vitro study. Voriconazole prolonged survival and reduced fungal load in the kidneys and brain in those mice infected with strains with MICs of<0.25 μg/ml, while in mice infected with strains with MICs of 0.5 to 2 μg/ml, the efficacy was varied and strain dependent and in mice infected with the strain with a MIC of 4 μg/ml, the antifungal did not show efficacy. Voriconazole reduced galactomannan antigenemia against practically all strains with a MIC of<4 μg/ml. Our results demonstrate that some relationship exists between voriconazole MICs and in vivo efficacy; however, further studies testing additional strains are needed to better ascertain which MIC values can predict clinical outcome.

Original languageEnglish (US)
Pages (from-to)1404-1408
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume57
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Aspergillus fumigatus
Infection
Body Weight
In Vitro Techniques
Voriconazole
Kidney
Brain
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Evaluation of the in vitro activity of voriconazole as predictive of in vivo outcome in a murine aspergillus fumigatus infection model. / Salas, Valentina; Javier Pastor, F.; Calvo, Enrique; Sutton, Deanna A.; Fothergill, Annette W.; Guarro, Josep.

In: Antimicrobial Agents and Chemotherapy, Vol. 57, No. 3, 03.2013, p. 1404-1408.

Research output: Contribution to journalArticle

Salas, Valentina ; Javier Pastor, F. ; Calvo, Enrique ; Sutton, Deanna A. ; Fothergill, Annette W. ; Guarro, Josep. / Evaluation of the in vitro activity of voriconazole as predictive of in vivo outcome in a murine aspergillus fumigatus infection model. In: Antimicrobial Agents and Chemotherapy. 2013 ; Vol. 57, No. 3. pp. 1404-1408.
@article{903e070a9b0e47208552728cf5b3662e,
title = "Evaluation of the in vitro activity of voriconazole as predictive of in vivo outcome in a murine aspergillus fumigatus infection model",
abstract = "We have evaluated the in vitro activity of voriconazole against 61 strains of Aspergillus fumigatus by using broth microdilution, disk diffusion, and minimal fungicidal concentration procedures. We observed an excellent correlation between the results obtained with the three methods. Five percent of the strains showed MICs greater than or equal to the epidemiological cutoff value (ECV; 1 μg/ml). To assess whether MICs were predictive of in vivo outcome, we tested the efficacy of voriconazole at 25 mg/kg of body weight daily in an immunosuppressed murine model of disseminated infection using 10 strains representing various patterns of susceptibility to the drug as determined by the in vitro study. Voriconazole prolonged survival and reduced fungal load in the kidneys and brain in those mice infected with strains with MICs of<0.25 μg/ml, while in mice infected with strains with MICs of 0.5 to 2 μg/ml, the efficacy was varied and strain dependent and in mice infected with the strain with a MIC of 4 μg/ml, the antifungal did not show efficacy. Voriconazole reduced galactomannan antigenemia against practically all strains with a MIC of<4 μg/ml. Our results demonstrate that some relationship exists between voriconazole MICs and in vivo efficacy; however, further studies testing additional strains are needed to better ascertain which MIC values can predict clinical outcome.",
author = "Valentina Salas and {Javier Pastor}, F. and Enrique Calvo and Sutton, {Deanna A.} and Fothergill, {Annette W.} and Josep Guarro",
year = "2013",
month = "3",
doi = "10.1128/AAC.01331-12",
language = "English (US)",
volume = "57",
pages = "1404--1408",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - Evaluation of the in vitro activity of voriconazole as predictive of in vivo outcome in a murine aspergillus fumigatus infection model

AU - Salas, Valentina

AU - Javier Pastor, F.

AU - Calvo, Enrique

AU - Sutton, Deanna A.

AU - Fothergill, Annette W.

AU - Guarro, Josep

PY - 2013/3

Y1 - 2013/3

N2 - We have evaluated the in vitro activity of voriconazole against 61 strains of Aspergillus fumigatus by using broth microdilution, disk diffusion, and minimal fungicidal concentration procedures. We observed an excellent correlation between the results obtained with the three methods. Five percent of the strains showed MICs greater than or equal to the epidemiological cutoff value (ECV; 1 μg/ml). To assess whether MICs were predictive of in vivo outcome, we tested the efficacy of voriconazole at 25 mg/kg of body weight daily in an immunosuppressed murine model of disseminated infection using 10 strains representing various patterns of susceptibility to the drug as determined by the in vitro study. Voriconazole prolonged survival and reduced fungal load in the kidneys and brain in those mice infected with strains with MICs of<0.25 μg/ml, while in mice infected with strains with MICs of 0.5 to 2 μg/ml, the efficacy was varied and strain dependent and in mice infected with the strain with a MIC of 4 μg/ml, the antifungal did not show efficacy. Voriconazole reduced galactomannan antigenemia against practically all strains with a MIC of<4 μg/ml. Our results demonstrate that some relationship exists between voriconazole MICs and in vivo efficacy; however, further studies testing additional strains are needed to better ascertain which MIC values can predict clinical outcome.

AB - We have evaluated the in vitro activity of voriconazole against 61 strains of Aspergillus fumigatus by using broth microdilution, disk diffusion, and minimal fungicidal concentration procedures. We observed an excellent correlation between the results obtained with the three methods. Five percent of the strains showed MICs greater than or equal to the epidemiological cutoff value (ECV; 1 μg/ml). To assess whether MICs were predictive of in vivo outcome, we tested the efficacy of voriconazole at 25 mg/kg of body weight daily in an immunosuppressed murine model of disseminated infection using 10 strains representing various patterns of susceptibility to the drug as determined by the in vitro study. Voriconazole prolonged survival and reduced fungal load in the kidneys and brain in those mice infected with strains with MICs of<0.25 μg/ml, while in mice infected with strains with MICs of 0.5 to 2 μg/ml, the efficacy was varied and strain dependent and in mice infected with the strain with a MIC of 4 μg/ml, the antifungal did not show efficacy. Voriconazole reduced galactomannan antigenemia against practically all strains with a MIC of<4 μg/ml. Our results demonstrate that some relationship exists between voriconazole MICs and in vivo efficacy; however, further studies testing additional strains are needed to better ascertain which MIC values can predict clinical outcome.

UR - http://www.scopus.com/inward/record.url?scp=84874100340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874100340&partnerID=8YFLogxK

U2 - 10.1128/AAC.01331-12

DO - 10.1128/AAC.01331-12

M3 - Article

C2 - 23295918

AN - SCOPUS:84874100340

VL - 57

SP - 1404

EP - 1408

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 3

ER -